Obesity drug stocks continue to dominate market attention — and Structure Therapeutics (GPCR) is quickly emerging as one of the sector’s strongest momentum stories.
We first highlighted GPCR back in late June when the stock traded near $22. Today, it has surged to $66, tripling in value after the company released impressive topline data for its oral GLP-1 drug, aleniglipron. Early results not only exceeded expectations but also outperformed competing treatments from giants like Eli Lilly and Novo Nordisk, sending a wave of optimism through the biotech space.
Wall Street Is Taking Notice
Fueling the rally, BMO Capital raised its price target on GPCR to $130, maintaining an outperform rating.
According to Investing.com, the firm increased its probability of success for aleniglipron from 55% to 70%, and now forecasts $3.8 billion in peak adjusted sales by 2035.
These upgrades point to one thing: Wall Street believes GPCR could become a major player in the fast-growing metabolic and obesity treatment market.
Don’t Forget Viking Therapeutics (VKTX)
Structure Therapeutics isn’t the only name to watch.
We’ve also been following Viking Therapeutics (VKTX) — another biotech innovator developing promising obesity treatments.
Currently trading around $36.55, VKTX could be gearing up for another explosive move if its obesity trials continue producing strong results.
Recent updates include:
-
Initiation of the VANQUISH Phase 3 program for VK2735, a dual GLP-1/GIP agonist
-
Progress on both oral and injectable formulations
-
Plans for a monthly maintenance regimen study beginning soon
-
Anticipated Phase 2 results from the VENTURE-Oral Dosing study in the second half of the year
VKTX may be setting up for a significant rerating as the GLP-1 race accelerates.
Why These Stocks Matter
The obesity drug market is expanding at a staggering pace. With new data, innovative delivery methods, and increasing patient demand, the space is attracting enormous investment — and substantial trading opportunities.
GPCR’s recent move shows what can happen when strong trial data meets strong market sentiment. VKTX may not be far behind if upcoming results confirm the company’s early promise.
Ian Cooper continues to track these names closely as part of his disciplined, data-backed approach to trading — combining technical analysis, fundamentals, and news-driven catalysts.
If you’re interested in leveraged opportunities in fast-moving sectors like biotech, Ian’s Premium Options Strategies provide step-by-step guidance designed for today’s market.